查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1198339

單細胞基因組測序市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)

Single-Cell Genome Sequencing Market- Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

單細胞基因組測序市場預計在 2022 年至 2027 年的預測期內以 15.2% 的複合年增長率增長。

COVID-19 大流行對所研究的市場產生了積極影響。 關於 COVID-19 對單細胞測序的影響的各種研究已經發表。 例如，2020 年 9 月發表的題為“COVID-19 患者免疫反應的單細胞景觀”的研究表明，由嚴重急性呼吸系統綜合症冠狀病毒 2 (SARS-CoV-2) 感染引起的冠狀病毒病 (COVID-19)這項名為“疾病嚴重程度與宿主免疫反應之間的關係尚未完全了解”的研究對疾病嚴重程度與宿主免疫反應之間的關係知之甚少。 單細胞測序顯示 COVID-19 患者的大多數細胞類型都有強烈的干擾素-ALPHA 反應和整體急性炎症反應。 這些研究提供了對單細胞測序在 COVID-19 中應用的見解。 同樣，在 2022 年 2 月，另一項名為“Integrating Single-Cell Sequencing Data with GWAS Summary Statistics Reveals CD16+Monocytes and Memory CD8+T Cells Involved in Severe COVID-19”的研究將顯示輕度和重度感染之間的差異。據報導，感染之間存在較大的基因調節免疫學變化。 包括遺傳風險基因表達升高、炎性細胞因子增加和功能性免疫細胞亞群增加，這些都會加劇疾病的嚴重程度。 因此，此類研究提供了對 COVID-19 的洞察力，從而增加了未來的市場增長。

疾病增多、主要市場參與者的舉措以及資金增加等因素預計將推動市場增長。 新興市場的發展可能會推動該地區的藥物開發進程，並最終由於設備提供的優勢而導致研究市場的擴大。 例如，根據 2020 年 9 月發表的一篇文章，有 220 萬，比美國國立衛生研究院 (NIH) 資助的 2300 億美元的國家衛生研究發表的與生物製劑或靶標相關的研究多出 21%。 生物技術領域的此類資金增加了 PCR 設備（包括單細胞測序）的研究和使用，推動了市場增長。 此外，市場參與者和研究機構之間使用測序儀研究和開發新的診斷和治療方法的合作也在推動市場的增長。 例如，2020 年 1 月，Illumina 和以色列的 Danyel Biotech 報告說，以色列魏茨曼科學研究所的科學家正在使用 Illumina 的下一代測序 (NGS) 技術。 Weizmann 是單細胞基因組學的先驅，Illumina 的技術將使研究所的研究人員能夠進一步發展這一新興的研究領域。 新安裝的系統還將擴大以色列的基因組研究能力。 實驗室正在使用 NovaSeq 6000 系統研究免疫系統內的細胞如何與健康組織和腫瘤細胞相互作用。 NovaSeq 6000 的使用使研究人員能夠對基因組、表觀基因組和轉錄組（RNA 序列）進行測序，這有望推動被調查市場的增長。 因此，由於上述因素，未來市場可能會增長。

但是，與單細胞基因組測序相關的分析挑戰可能會阻礙市場增長。

單細胞基因組測序市場趨勢

預計在預測期內 PCR 領域將佔據重要的市場份額

預計 PCR 部分在預測期內將佔據很大的市場份額。

主要市場參與者的舉措（例如產品發布和合作研究）等因素預計將在預測期內推動市場增長。 細分市場的增長是由產品引入市場推動的。 例如，2020 年 6 月，Stilla Technologies 推出了全球首款六色數字 PCR 儀器之一，名為“六色稜鏡”。 該設備可廣泛應用於腫瘤、傳染病、基因治療、疾病監測、食品檢測等領域。 同樣，2022 年 7 月，Bio-Rad 推出了 CFX Opus Deepwell 實時 PCR 檢測系統。 Bio-Rad 的 CFx Opus Deepwell 實時 PCR 檢測系統旨在支持研究人員開發核酸檢測分析。

此外，參與者之間的戰略合作推動了該細分市場的發展，以加強全球競爭。 例如，2021 年 10 月，PerkinElmer 和 Honeycomb Biotechnologies 宣布推出全球首個用於單細胞分離和分析的 HIVE scRNAseq 解決方案。 HIVE 解決方案利用便攜式手持設備捕獲、存儲和製備各種細胞類型的 RNA-Seq 文庫，包括粒細胞、腎單位、肝細胞和神經元等脆弱和不穩定的細胞。 由於 HIVE 不需要專門的設備，它擴大了實驗室進行基礎、轉化、臨床和臨床前研究的可能性。

因此，由於上述因素，市場的 PCR 部分預計在預測期內將出現大幅增長。

北美有望在預測期內主導市場

預計在預測期內，北美將佔據市場的主導份額。

疾病流行率上升以及主要市場參與者的產品發布和擴張等因素預計將推動該地區的市場增長。 根據美國癌症協會雜誌發表的“2021 年癌症統計數據”，美國估計有 190 萬新癌症病例和 608,570 例死亡病例將顯著推動市場。 同樣，根據 Globocan 2020 的數據，2020 年該國估計將有 195,449 例新癌症病例。 預計在預測期內，該國癌症患者人數將增加，從而推動市場增長。

此外，基於單細胞測序的新產品的推出將極大地推動市場的增長。 例如，2020 年 9 月，Roche獲得美國食品藥品監督管理局 (FDA) 的批准，用於美國全自動 cobas 6800/8800 系統的 cobas HIV-1/HIV-2 定性檢測。 該測試將幫助醫療保健專業人員在一次測試中做出確認 HIV 診斷和確定適當治療所需的關鍵 HIV-1 和 HIV-2 區分。 2021 年 10 月，Takara Bio Inc. 的全資子公司 Takara Bio USA Inc. 推出了用於 ICELL8 cx 單細胞系統的 SMART-Seq Pro 試劑盒。 科學家們將使用這種自動化的單細胞 RNA-seq 技術同時從 1,500 多個單細胞中收集全長轉錄組數據，這些數據來自廣泛的樣本類型，包括巨大而脆弱的成人心肌細胞。 此外，在 2020 年 3 月，為了應對 COVID-19 公共衛生挑戰，基於劍橋的推理創建了世界上第一個用於合成異構單細胞 RNA 測序 (scRNA-seq) 數據集的軟件資源。宣布它做到了。 這個圖書館了解超過 1 億篇非結構化生物醫學論文，nferX 增強智能使您能夠將科學文獻中的新發現與單細胞水平的深層生物信號相關聯它配備了技術。

因此，由於這些因素，所研究的市場預計在預測期內將顯著增長。

單細胞基因組測序市場競爭者分析

市場部分分散，由幾個主要參與者組成。 目前主導市場的一些公司是 Fluidigm Corporation、QIAGEN、Illumina, Inc.、F. Hoffmann-La Roche Ltd. 和 ThermoFisher Scientific, Inc.。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動力
    • 對單細胞基因組學的高研發投資
    • 增加 SCG 中心和核心設施
  • 市場製約因素
    • 與單細胞基因組測序相關的分析挑戰
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（按價值計算的市場規模:百萬美元）

  • 產品名稱
    • 設備
    • 試劑
  • 技術領域
    • 音序器
    • 聚合□鏈反應
    • 微陣列
    • 其他
  • 申請
    • 癌症
    • 免疫學
    • 微生物學
    • 其他
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • 10x Genomics
    • BD
    • BGI
    • Bio-Rad Laboratories, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Fluidigm Corporation
    • Illumina, Inc.
    • Oxford Nanopore Technologies plc.
    • PacBio
    • QIAGEN
    • Takara Bio Inc
    • ThermoFisher Scientific, Inc.

第七章市場機會與未來趨勢

簡介目錄
Product Code: 90594

The Single-cell Genome Sequencing Market is projected to register a CAGR of 15.2% during the forecast period 2022-2027.

The COVID-19 pandemic had a positive effect on the studied market. Various research studies have been published about the impact of COVID-19 on single-cell sequencing. For Instance, in September 2020, research published titled "Single-cell landscape of Immunological Responses in Patients with COVID-19" stated that coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the relationship between disease severity and the host immune response is not fully understood. When single-cell sequencing was performed, most cell types in patients with COVID-19 showed a strong interferon-α response and an overall acute inflammatory response. Such studies provide inside into the application of single-cell sequencing on COVID-19. Similarly, in February 2022, another research study titled "Integrating Single-Cell Sequencing Data with GWAS Summary Statistics Reveals CD16+ Monocytes and Memory CD8+T Cells Involved in Severe COVID-19" stated that there was a major genetics-modulated immunological shift between mild and severe infection, including an elevated expression of genetics-risk genes, increase in inflammatory cytokines, and of functional immune cell subsets aggravating disease severity, which provides novel insights into parsing the host genetic determinants that influence peripheral immune cells in severe COVID-19. Hence, such studies provide insight into COVID-19 and thus increase the market growth in the future.

Factors such as increasing diseases, initiatives by key market players, and increased funding are expected to increase the market growth. Rising disease prevalence is also likely to boost the drug development processes in the region, ultimately leading to the studied market expansion owing to the benefits offered by the devices. For Instance, as per the article titled ' United States Tax Dollars Funded Every New Pharmaceutical in the Last Decade' published in September 2020 2.2 million published research related to the biological drugs or targets of which 21% acknowledged funding from National Institutes of Health (NIH) of more than than USD 230 Billion. Such funding in the biotechnology field increases the research and the usage of PCR devices (including single-cell sequencing), boosting the market's growth. The collaboration among the market players and research institutes for the research and development of new diagnostics and treatment methods with the help of the sequencing method is also boosting the market's growth. For Instance, in January 2020, Illumina and Israel-based Danyel Biotech reported that scientists at the Weizmann Institute of Science in Israel are now using Illumina's next-generation sequencing (NGS) technology. Weizmann has been a pioneer of single-cell genomics, and Illumina's technology will enable the Institute's researchers to continue advancing this fast-growing field of research. The newly-installed system also expands genomic research capacity within Israel. The institutes are using NovaSeq 6000 system to investigate how cells within the immune system interact with healthy tissue and tumor cells. Since the use of NovaSeq 6000 enables researchers to sequence the genome, epigenome, and transcriptome (RNA sequence), it is expected to drive the growth of the studied market. Thus, due to the abovementioned factors, the market is likely to grow in the future.

However, analytical challenges related to single-cell genome sequencing will hinder the market's growth.

Single Cell Genome Sequencing Market Trends

PCR Segment is Expected to Hold a Significant Market Share Over the Forecast Period

The PCR segment is expected to hold a significant share in the market over the forecast period.

Factors such as initiatives by key market players such as product launches and collaborations are expected to increase the market growth in the forecast period. The market segment's growth is boosted by the launch of products in the market. For instance, in June 2020, Stilla Technologies launched one of the world's first six-color digital PCR instruments named 'the six-color Prism'. This system can be used widely in oncology, infectious disease, gene therapy, disease monitoring, and food testing. Similarly, in July 2022 Bio-Rad launched CFX Opus Deepwell real-time PCR detection system. Bio-Rad's CFx Opus Deepwell Real-time PCR Detection system is designed to support research in developing nucleic acid detection assays.

Additionally, the market segment is boosted by the strategic collaboration among the players to strengthen the opposition worldwide. For instance, in October 2021, PerkinElmer and Honeycomb Biotechnologies announced the launch of the first-of-its-kind HIVE scRNAseq Solution for single-cell isolation and analysis. The HIVE solution leverages a portable, handheld device for the capture, storage, and RNA-Seq library preparation of a diverse range of cell types, including fragile and labile cells such as granulocytes, nephrons, hepatocytes, and neurons. The HIVE solution requires no specialized instrumentation and expands opportunities for laboratories pursuing basic, translational, clinical, and preclinical research.

Thus, owing to the abovementioned factors, the PCR segment of the market is expected to project considerable growth over the forecast period.

North America is Expected to Dominate the Market Over the Forecast Period

North America is expected to hold a dominant share in market over the forecast period.

Factors such as rising disease prevalence and product launches and expansions by key market players are expected to drive market growth in the region. According to Cancer Statistics 2021, published in the American Cancer Society Journal, an estimated 1.9 million new cancer cases are diagnosed and 608,570 cancer deaths in the United States, which will drive the market significantly. Similarly, according to data by Globocan 2020, the country's estimated number of new cancer cases in 2020 was 195,449. The number of cancer cases in the country is expected to increase during the forecast period, thus driving the market's growth.

Furthermore, launching new products based on single-cell sequencing will drive market growth significantly. For instance, in September 2020, Roche received United States Food and Drug Administration (FDA) approval for the Cobas HIV-1/HIV-2 Qualitative Test for use on the fully automated Cobas 6800/8800 Systems in the US. The test will help healthcare professionals confirm HIV diagnosis with a single test and differentiate HIV-1 and HIV-2, an important distinction needed to identify appropriate treatment options. In October 2021, Takara Bio USA, Inc., a fully owned subsidiary of Takara Bio Inc., launched the SMART-Seq Pro kit for the ICELL8 cx Single-Cell System. Scientists can collect full-length transcriptome data from over 1,500 single cells simultaneously using this automated single-cell RNA-seq technology from a wide range of sample types, including huge, delicate adult cardiomyocytes. Furthermore, in March 2020, to fight the COVID-19 public health problem, inference, a Cambridge-based company, announced the creation of a first-of-its-kind software resource that synthesizes disparate Single Cell RNA-sequencing (scRNA-seq) data sets. The library includes the nferX augmented intelligence technology, which enables machines to understand over 100 million unstructured biomedical papers and correlate emerging insights from scientific literature with deep biological signals at the single-cell level.

Thus, due to the such factors, the studied market is expected to grow significantly during the forecast period.

Single Cell Genome Sequencing Market Competitor Analysis

The market is partially fragmented and consists of several major players. Some companies currently dominating the market are Fluidigm Corporation, QIAGEN, Illumina, Inc., F. Hoffmann-La Roche Ltd., and ThermoFisher Scientific, Inc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 High R&D Investments in the Single cell Genomics
    • 4.2.2 Growing Number of SCG Centers and Core Facilities
  • 4.3 Market Restraints
    • 4.3.1 Analytical Challenges Related to Single-cell Genome Sequencing
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 Product
    • 5.1.1 Instruments
    • 5.1.2 Reagents
  • 5.2 Technology
    • 5.2.1 Sequencing
    • 5.2.2 PCR
    • 5.2.3 Microarray
    • 5.2.4 Others
  • 5.3 Application
    • 5.3.1 Cancer
    • 5.3.2 Immunology
    • 5.3.3 Microbiology
    • 5.3.4 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 10x Genomics
    • 6.1.2 BD
    • 6.1.3 BGI
    • 6.1.4 Bio-Rad Laboratories, Inc.
    • 6.1.5 F. Hoffmann-La Roche Ltd.
    • 6.1.6 Fluidigm Corporation
    • 6.1.7 Illumina, Inc.
    • 6.1.8 Oxford Nanopore Technologies plc.
    • 6.1.9 PacBio
    • 6.1.10 QIAGEN
    • 6.1.11 Takara Bio Inc
    • 6.1.12 ThermoFisher Scientific, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS